Screening for gestational diabetes mellitus
Hillier T, Vesco K, Whitlock E, Pettitt D, Pedula K, Beil T
Record ID 32011000583
English
Authors' objectives:
This review identifies and evaluates new evidence since the prior review on the risks and benefits of GDM screening at 24 weeks or later; it also newly reviews all of the available evidence pertaining to GDM screening prior to 24 weeks.
Authors' recommendations:
We found limited evidence to evaluate early screening for GDM prior to 24 weeks gestation, the purpose of which would be to detect previously unrecognized diabetes (GDM is defined as onset or first recognition of diabetes during pregnancy). Therefore, more research is needed before this question can be evaluated.
A recent good-quality randomized controlled trial reported that treatment of screen-detected women with mild GDM diagnosed after 24 weeks gestation reduces both maternal and composite neonatal health outcomes, without apparent harm—as reported in this RCT and in several other observational studies.
Details
Project Status:
Completed
URL for project:
http://www.ncbi.nlm.nih.gov/books/NBK43368/
Year Published:
2008
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Mass Screening
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.